Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis
Key Points. Acalabrutinib plus venetoclax and rituximab resulted in high clinical and molecular response rates in patients with TN MCLThis chemotherapy-fre